Phase 1 biotech Prometheus Biosciences sets terms for $125 million IPO

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, announced terms for its IPO on Monday.

The San Diego, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At thRead More